Company news

Krystal Biotech, Inc. news in 2024

Krystal Biotech, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

December 17, 2024

Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene Delivery to the Lung of AATD Patients and Increase in Lung AAT to Therapeutic Levels

December 11, 2024

Krystal Biotech Provides Update on EMA’s Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

December 8, 2024

Krystal Biotech to Present at Upcoming Investor Conferences

November 26, 2024

Krystal Biotech to Present at Stifel 2024 Healthcare Conference

November 11, 2024

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

November 5, 2024

Krystal Biotech Announces Third Quarter 2024 Financial Results and Provides Business Updates

November 3, 2024

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

October 27, 2024

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

September 12, 2024

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

September 5, 2024

Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté

August 27, 2024

Krystal Biotech Announces Second Quarter 2024 Financial Results and Provides Business Updates

August 4, 2024

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

July 25, 2024

Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference

June 4, 2024

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

May 14, 2024

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

May 7, 2024

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

May 5, 2024

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

May 1, 2024

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

April 25, 2024

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

April 21, 2024

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

April 3, 2024

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

February 27, 2024

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

February 25, 2024

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

February 19, 2024

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

February 12, 2024

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

February 7, 2024

Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

January 31, 2024

Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

January 3, 2024

Calls in 2024

Decks in 2024